Investment Research and Business Due Diligence
Tuesday, July 16, 2013
Hisamitsu Pharmaceutical initiates Phase 2 clinical study on a transdermal long acting system for the treatment of allergic rhinitis
Hisamitsu Pharmaceutical has initiated a Phase 2 clinical study on a transdermal long-acting system
for the treatment of allergic rhinitis (development code: HP-3060), which is under development in Japan.
HP-3060 is a systemic tape formulation developed by utilizing Hisamitsu’s TDDS (Transdermal Drug Delivery System) technology. We expect HP-3060 to be a new option for the treatment of allergic rhinitis by realizing its long-lasting effect by means of maintaining a stable blood concentration.
In the Phase 2 clinical study, the pharmacokinetics, efficacy, and safety will be studied by repeated-dose administration of HP-3060 or placebo in adults with allergic rhinitis. Hisamitsu aims to initiate a Phase 3 study during FY2014.
Enter your email address:
Share to Twitter
Share to Facebook
Share to Pinterest
Post Comments (Atom)